Key Highlights

Risk & Performance

Pipeline Risk Assessment

Based on historical performance

Low Risk

Score: 25/100

Failure Rate

0.0%

0 terminated/withdrawn out of 8 trials

Success Rate

100.0%

+13.5% vs industry average

Late-Stage Pipeline

38%

3 trials in Phase 3/4

Results Transparency

14%

1 of 7 completed trials have results

Key Signals

1 with results

Enrollment Performance

Analytics

Phase 3

3(37.5%)

Phase 1

3(37.5%)

Phase 2

2(25.0%)

8Total

Phase 3(3)

Phase 1(3)

Phase 2(2)

Activity Timeline

Global Presence

Loading network data...

Clinical Trials (8)

Showing 8 of 8 trials

NCT05467293Phase 2Completed

Phase 2, Multi-center, Randomized, Double- Masked and Placebo-Controlled Study of YP-P10 Ophthalmic Solution Compared to Placebo in Subjects With Dry Eye (ICECAP 1)

Role: lead

NCT01008163Phase 2Completed

A Dose-Finding, Efficacy and Safety Study of YY-351 in Patients With Type 2 Diabetes

Role: lead

NCT01201187Phase 3Completed

Efficacy and Safety Study of Combination of Ginkgo Extract and Ginseng Extract(YY-162)in Children With ADHD

Role: lead

NCT01526278Phase 1Completed

Pharmacokinetics of Maxmarvil® in Healthy Postmenopausal Women

Role: lead

NCT01536210Phase 3Completed

Efficacy and Safety Study of Combination of Ginkgo Extract and Ginseng Extract in Children With ADHD(Attention Deficit Hyperactivity Disorder)

Role: lead

NCT03240939Phase 1Completed

Pharmacokinetics and Safety/Tolerability of YY-201 in Comparison to Dutasteride and Tadalafil

Role: lead

NCT02133989Phase 3Unknown

Clopidogrel Resistance and Embolism in Carotid Artery Stenting

Role: collaborator

NCT02839122Phase 1Completed

A Study to Investigate the Pharmacokinetic Drug Interactions Between Dutasteride and Tadalafil in Healthy Male Subjects

Role: lead

All 8 trials loaded